Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2019’, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas under Gastrointestinal, Immunology, Infectious Disease and Undisclosed development targeting Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

C4X Discovery Holdings PLC

Genentech Inc

Morphic Therapeutic Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

C4X Discovery Holdings PLC

Genentech Inc

Morphic Therapeutic Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7 ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Companies Involved in Therapeutics Development

C4X Discovery Holdings PLC

Genentech Inc

Morphic Therapeutic Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Drug Profiles

ET-3764 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrolizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN-943 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGA4 and ITGB7 for Unspecified Indication – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Product Development Milestones

Featured News & Press Releases

Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis

Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head

Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials

Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943

Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease

Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan

Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire

Oct 22, 2018: Investigational subcutaneous formulation of Vedolizumab achieves and maintains clinical remission and mucosal healing at Week 52 in patients with moderately to severely active Ulcerative Colitis

Oct 08, 2018: New real-world data analyses support the long-term use of Entyvio (Vedolizumab) in bio-naïve patients for the treatment of moderate to severe ulcerative colitis or crohn's disease

Jul 19, 2018: Takeda reports positive top-line outcomes from VISIBLE 1 trial

Jul 18, 2018: Takeda Submits an Application for a New Indication of Entyvio (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Crohn’s Disease in Japan

Jul 02, 2018: Takeda Obtains New Drug Application Approval for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis in Japan

Jun 05, 2018: Analysis of real-world safety data shows gut-selective ENTYVIO (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFa-antagonist therapy in ulcerative colitis and Crohn's disease patients

Jun 03, 2018: Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

May 15, 2018: Bio-Rad Introduces Anti-Vedolizumab Antibodies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by C4X Discovery Holdings PLC, H1 2019

Pipeline by Genentech Inc, H1 2019

Pipeline by Morphic Therapeutic Inc, H1 2019

Pipeline by Protagonist Therapeutics Inc, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports